Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Therapeutic Drug Carrier Systems
Factor de Impacto: 2.9 Factor de Impacto de 5 años: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimir: 0743-4863
ISSN En Línea: 2162-660X

Volumes:
Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i2.20
35 pages

Oral Delivery of Proteins: Progress and Prognostication

Rakhi B. Shah
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, TX 79106
Fakhrul Ahsan
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, USA
Mansoor A. Khan
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, TX 79106

SINOPSIS

The delivery of proteins has gained momentum with the development of biotechnology sector that provided large-scale availability of therapeutic proteins. The availability is mostly due to the advances in recombinant DNA technology. The low oral bioavailability, however, continues to be a problem for several proteins because of their large molecular size, low permeation through biological membranes, and susceptibility to molecular changes in both biological and physical environments. The demand for effective delivery of proteins by the oral route has brought a tremendous thrust in recent years both in the scope and complexity of drug delivery technology. The important therapeutic proteins and peptides being explored for oral delivery include insulin, calcitonin, interferons, human growth hormone, glucagons, gonadotropin-releasing hormones, enkephalins, vaccines, enzymes, hormone analogs, and enzyme inhibitors. This article reviews the progress in oral delivery of these proteins, provides comments on the strategies to improve their oral bioavailability, and highlights their current market trends.


Articles with similar content:

Recent Progress in Polymeric Gene Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 4
Sanjeev Kumar Mendiratta, Khursheed Anwer, B. G. Rhee
Bioconjugates: Harnessing Potential for Effective Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 2
Piush Khare, Nitin K. Jain, Aviral Jain, Vandana Soni, Arvind Gulbake, Sanjay Kumar Jain
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta
Recent Advances in the Stabilization of Proteins Encapsulated in Injectable PLGA Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 1
Steven P. Schwendeman
Pulmonary Drug Delivery Systems: Recent Developments and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Th. F. Vandamme, N. Butz, H. M. Courrier